GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Texas, on Wednesday published a 47-page report titled “The Case for Healthcare Freedom" as a roadmap to "Make American ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...